"Today marks another great milestone in our partnership with the JDRF in collaboration with the Helmsley Charitable Trust to advance CGM technology for the artificial pancreas, which began several years ago with the JDRF CGM studies and continues through multiple artificial pancreas studies today," said Katie Szyman, President of the Diabetes business of Medtronic. "We are also excited to unveil the optical based glucose sensing technology we acquired several years ago. Advancing sensor accuracy and reliability is core to both organizations' missions to enable people with diabetes to live longer, healthier lives."CGM devices provide both a real-time snapshot of the glucose level of a person with diabetes, as well as trend information on whether glucose is moving upwards or downwards, and how fast. The devices also provide warnings when the glucose is becoming too high or too low. JDRF's landmark CGM trials have shown that using CGM can significantly improve diabetes control and decrease the frequency of high and low blood sugars when used regularly. Today, these sensors are being used as part of artificial pancreas systems, ones that will reduce the amount of high and low blood sugar people with diabetes experience by automating insulin delivery some of the time. In the future, artificial pancreas systems that restore non-diabetes like glucose levels and are automated most of the time will require advanced sensors with increased accuracy and error detection capabilities. Medtronic has been a pioneer in artificial pancreas systems and developed the first closed loop product, Paradigm Veo, that automatically suspends insulin delivery if the sensor glucose value is equal to or below the low threshold value. This system is commercially available outside of the United States and Medtronic is conducting a pivotal trial to obtain Food and Drug Administration (FDA) approval.
JDRF Through The Joint JDRF-Helmsley Charitable Trust Initiative Partners With Medtronic To Advance Continuous Glucose Monitoring Towards Artificial Pancreas Systems
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts